title: Doctors of interest. Recipients of suspect drug-company payments academic medical centers, have drawing attention of federal fraud enforcers.
abstract: As the federal government begins to focus more on wasteful healthcare spending, doctors' relationships with drug companies are coming under scrutiny. Many times, those relationships are legitimate, says Mary Riordan, left, a senior counsel to HHS' inspector general's office. "There are other situations where the relationship between the doctor and the manufacturer is suspect".
authors.forename: Joe
authors.initials: J
authors.lastname: Carlson
mesh_terms: D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D005607:Fraud / Q000191:economics / Q000331:legislation & jurisprudence*; D006801:Humans; D010820:Physicians / Q000191:economics / Q000331:legislation & jurisprudence*; D014481:United States; D014483:United States Dept. of Health and Human Services